drugset / Trial / NCT02057796

Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3

NCT02057796 ↗

Phase 4 Completed 1050 enrolled ANRS, Emerging Infectious Diseases
RandomizedParallel-groupOpen-labelPrevention

Summary

In countries with a high tuberculosis (TB) prevalence, TB and invasive bacterial infections are leading causes of early death in patients who initiate antiretroviral therapy (ART) with advanced immunodeficiency. We hypothesize that a systematic 6-month empirical TB treatment initiated 2 weeks before the introduction of ART in HIV-infected adults with severe immunosuppression (CD4\<100/mm3) and no overt evidence of TB will reduce the risk of death and invasive bacterial infections. This strategy will be compared to one of extensive TB testing using point-of-care tests (Xpert MTB/RIF® and urine lipoarabinomanan LAM) and chest X-ray to identify and treat only patients with at least one positive test suggestive of TB.

Timeline

Start
2014-09
Primary completion
2018-04
Completion
2018-04

Outcome

Missed primary endpoint

paper systematic treatment for tuberculosis was not superior to test-guided treatment in reducing the rate of death or invasive bacterial disease over 24 or 48 weeks PMID 32558469 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ethambutol Small molecule — —
Subject Isoniazid Small molecule — —
Subject Pyrazinamide Small molecule — —
Subject Rifampicin Small molecule — —
Background Atripla Unknown — —
Background Combivir Unknown — —
Background Efavirenz Other / unclassified — —
Background Truvada Unknown — —